Clay Siegall is the co-founder and CEO of the Seattle Genetics. As the top leading cause of death in the globe, Siegall is committed to finding a cure for cancer. He has made significant achievements in developing an Antibody Drug Conjugate (ADC’s) through his leadership in the firm. The drug selectively destroys the cancer cells and leaves the healthy cells active. Besides producing the ADC’s, they have pooled their footprints to increase the use of Adcetris to other diseases apart from cancer.
Adcetris is mostly used for cancer treatment, and it is the main drug manufactured by the business. Clay Siegall says that they have tested the drug on lymphomas for seventy different cases. The company also has the plan to add more personnel to produce more Adcetris drugs. Today the firm has more than eight hundred workers. Furthermore, they have expanded their growth strides to building twenty offices in Switzerland.
His quest for providing support to individuals and research activities has led the company to be one of the leading firms in the cancer investigation community. He has the mindset of ending cancer in the future. Moreover, he also wishes to unleash more twelve cancer drugs. This has been a source of hope for the people living with cancer. His vast experience from the different sectors he has served has allowed him to lead his company in the successful paths. For instance, Clay Siegall has worked with the Nation Institute of Health and Cancer.
About the Seattle Genetics
The biotechnological firm led by Siegall produces preclinical and clinical products. It was launched in 1998 and has been providing innovative cancer drugs, the ADC’s over the years. It has worked in partnership to research, provide scientific innovation and drug advancement activities. This includes partners like Genentech, Curagen, Bayer Pharmaceuticals Corporation and Medimmune.
The Seattle Genetics CEO is appointed as a Mirna Therapeutics Company’s Board of Director
Mirna announced the appointment of Clay Siegall as the Board of Directors’ member and outside director in 2013. Founded in 2007, the Company is focused on therapeutics microRNA. With the presence of Dr. Clay in the firm, they are currently into cancer research. Dr. Paul Lammers, the CEO of Mirna says that they are excited to have an experienced man around their activities. They have high expectation from Dr. Clay to guide them in the microRNA therapeutics advancements.